Last reviewed · How we verify

CT-P47 AI (tocilizumab)

Celltrion · Phase 3 active Biologic

CT-P47 AI (tocilizumab) is a IL-6 receptor antagonist (monoclonal antibody biosimilar) Biologic drug developed by Celltrion. It is currently in Phase 3 development for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

CT-P47 is a biosimilar of tocilizumab that blocks the interleukin-6 (IL-6) receptor to reduce inflammatory signaling.

CT-P47 is a biosimilar of tocilizumab that blocks the interleukin-6 (IL-6) receptor to reduce inflammatory signaling. Used for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

At a glance

Generic nameCT-P47 AI (tocilizumab)
SponsorCelltrion
Drug classIL-6 receptor antagonist (monoclonal antibody biosimilar)
TargetIL-6 receptor (IL-6R)
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Tocilizumab is a humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated inflammation. By blocking this key cytokine pathway, it suppresses systemic inflammation and is used to treat autoimmune and inflammatory conditions. CT-P47 is Celltrion's biosimilar candidate designed to replicate the efficacy and safety profile of the reference tocilizumab.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CT-P47 AI (tocilizumab)

What is CT-P47 AI (tocilizumab)?

CT-P47 AI (tocilizumab) is a IL-6 receptor antagonist (monoclonal antibody biosimilar) drug developed by Celltrion, indicated for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

How does CT-P47 AI (tocilizumab) work?

CT-P47 is a biosimilar of tocilizumab that blocks the interleukin-6 (IL-6) receptor to reduce inflammatory signaling.

What is CT-P47 AI (tocilizumab) used for?

CT-P47 AI (tocilizumab) is indicated for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis, Systemic sclerosis-associated interstitial lung disease.

Who makes CT-P47 AI (tocilizumab)?

CT-P47 AI (tocilizumab) is developed by Celltrion (see full Celltrion pipeline at /company/celltrion).

What drug class is CT-P47 AI (tocilizumab) in?

CT-P47 AI (tocilizumab) belongs to the IL-6 receptor antagonist (monoclonal antibody biosimilar) class. See all IL-6 receptor antagonist (monoclonal antibody biosimilar) drugs at /class/il-6-receptor-antagonist-monoclonal-antibody-biosimilar.

What development phase is CT-P47 AI (tocilizumab) in?

CT-P47 AI (tocilizumab) is in Phase 3.

What are the side effects of CT-P47 AI (tocilizumab)?

Common side effects of CT-P47 AI (tocilizumab) include Infection (including serious infections), Elevated liver enzymes, Neutropenia, Hyperlipidemia, Gastrointestinal perforation.

What does CT-P47 AI (tocilizumab) target?

CT-P47 AI (tocilizumab) targets IL-6 receptor (IL-6R) and is a IL-6 receptor antagonist (monoclonal antibody biosimilar).

Related